Centro De Inmunologia Molecular

Centro De Ingenieria Genetica Y Biotechnologia

Centro De Immunologia Molecular

Biorec S.a.

Centro De Inmumologia Molecular

Centro De Ingenieria Genetica Y Biotecnologia

Gertrudis Rojas Dorantes

Kalet León Monzón

Tania Carmenate Portilla

Jorge Victor Gavilondo Cowley

Ernesto Moreno Frias

Ana Victoria Casadesus Pazos

Humberto Lamdan Ordas

Marta Ayala Avila

Yasmiana Muñoz Pozo

Amaury Pupo Meriño

Lincidio Perez Sanchez

Yaima Tundidor Cabado

Ariel Talavera Perez

Ernesto 5Ta Avenida Edificio Bbe Moreno Frias

Loudes Tatiana Roque Navarro

Cristina María Mateo De Acosta Del Rio

Mabel Consejal Veiga No 110 Rodriguez Gonzalez

Yasmiana MUÑOZ Pozo

Lincidio PÉREZ SÁNCHEZ

Jorge Víctor Gavilondo Cowley

Amaury Pupo MERIÑO

Mabel Rodriguez Gonzalez

Cristina Maria Mateo De Acosta Del Rio

Yasmiana Munoz Pozo

Amaury Pupo Merino

The present invention relates to the field of Biotechnology, particularly to a method based on the introduction of a single mutation in the genes encoding the human IL-2 and the muteins derived thereof that results in increased secretion levels in different hosts without affecting their biological functions. In particular, these mutations are based on a non-conservative change in the amino acid located in position 35 in the primary sequence of human IL-2, preferably the substitutions are K35E, K35D and K35Q. Another object of the present invention are the expression systems used to obtain both the recombinant human IL-2 and the muteins derived thereof using the method described in this invention. The above-mentioned method is useful to improve the production efficiency of the recombinant human IL-2 and the muteins derived thereof both at laboratory and industrial scales. The proteins obtained using this method can be used for therapeutic purposes as well as in the in vitro expansion of T cells for adoptive transfer therapies.

Method for increasing the secretion levels of interleukin 2 and muteins thereof by introducing a point mutation

This invention provides new antibodies (Ab) and fragments that recognize the extracellular region of the human epidermal growth factor receptor (hEGFR) with a higher affinity than the Ab nimotuzumab, thus been able to recognize more efficiently lines with medium expression of EGFR. The present invention also relates to pharmaceutical compositions comprising as active principle the disclosed Abs and fragments and their use in the therapy of tumors with EGFR expression. In addition, it relates to the use of the Abs and fragments disclosed linked to a radioisotope or fluorophore for the localization of EGFR positive tumors. Additionally, the Abs and fragments disclosed can be used in the directionalization of the immune response to EGFR positive tumor cells when they are fused to protein or protein domains of immunological interest.

Antibodies with increased affinity for the epidermal growth factor receptor and fragments derived therefrom

The present invention relates to new monoclonal antibodies and fragments of these antibodies, which have dual specificity and high affinity for N-acetyl GM3 and N-glycolyl GM3 and do not recognize other gangliosides. In another aspect, the present invention relates to the use of these antibodies and their fragments in the therapy of tumors characterized by a significant expression of any of the two antigens recognized by these antibodies, or a mixed expression of both antigens. Likewise, the invention relates to the use of these antibodies in the diagnosis of tumors expressing at least one of the two variants of the GM3 ganglioside.

Recombinant antibodies having dual specificity for gangliosides and use thereof

The present invention reveals human recombinant antibodies that recognize the human Vascular Endothelium Growth Factor A (VEGF-A), block its interaction with the VEGFR2 receptor, and interfere with its proliferative effect in vitro and pro-angiogenic effect in vivo. The antibodies identify an epitope on human VEGF-A different from any other previously reported, and were obtained by combining one immunoglobulin light chain variable region with other three heavy chain ones. The antibodies were obtained by human immunoglobulin variable region mutagenesis, and can be employed for the immunotherapy of pathological entities associated with an increase in vasculature, such as age-related macular degeneration, cancer, and others.

Recombinant antibodies to the vascular endothelial growth factor (VEGF) which are obtained by means of mutagenesis of variable regions

Growing community of inventors

La Habana, Cuba

Gertrudis Rojas Dorantes